17th Mar 2025

Scottish Government announcement of investment to support national pharmacogenetic testing of CYP2C19 in Stroke patients and MT-RNR1 in newborn babies in NHS Scotland.

genedrive plc (AIM: GDR), the point-of-care pharmacogenetic testing company, is pleased to note...

14th Mar 2025

North West Anglia Foundation NHS Trusts’ Peterborough City Hospital implements the Genedrive® CYP2C19-ID Kit for routine clinical use

genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, is pleased to anno...

6th Jan 2025

Genedrive® CYP2C19 ID Kit clinical performance published

Superior performance to laboratory test and alternative available point of care platforms ge...